

# Irit Avivi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1755416/publications.pdf>

Version: 2024-02-01

172  
papers

7,935  
citations

172386

29  
h-index

54882

84  
g-index

178  
all docs

178  
docs citations

178  
times ranked

10676  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
2	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	0.6	539
3	<sup>18</sup> F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients. <i>Journal of Nuclear Medicine</i> , 2010, 51, 25-30.	2.8	352
4	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	15.2	179
5	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.	2.2	174
6	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naïve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e448-e458.	2.2	168
7	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019, 6, e67-e78.	2.2	146
8	Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy – A Single-Center Prospective Cohort Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 788-794.	0.6	125
9	Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. <i>Nature Medicine</i> , 2021, 27, 491-503.	15.2	118
10	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	1.2	88
11	Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1782-1791.	0.8	84
12	Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2013, 88, 400-405.	2.0	78
13	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-508.	0.8	78
14	Management of Hematologic Malignancies: Special Considerations in Pregnant Women. <i>Drugs</i> , 2015, 75, 1725-1738.	4.9	68
15	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 874-882.	1.7	67
16	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2021, 195, 186-193.	1.2	65
17	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents – a multicenter historical prospective study. <i>Annals of Hematology</i> , 2019, 98, 1927-1932.	0.8	56
18	Anti-CD20 monoclonal antibodies: Beyond B-cells. <i>Blood Reviews</i> , 2013, 27, 217-223.	2.8	55

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. <i>Haematologica</i> , 2017, 102, 1913-1922.	1.7	52
20	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	1.2	47
21	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	1.2	45
22	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2019, 6, e551-e561.	2.2	45
23	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 243-243.	0.6	42
24	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
25	Polymicrobial pulmonary infection in patients with hematological malignancies: prevalence, co-pathogens, course and outcome. <i>Infection</i> , 2016, 44, 491-497.	2.3	40
26	Extended vs Bolus Infusion of Broad-Spectrum $\beta$ -Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. <i>Clinical Infectious Diseases</i> , 2018, 67, 1153-1160.	2.9	38
27	Prognostic factors in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2005, 12, 62-67.	1.2	33
28	Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016, 172, 89-96.	1.2	33
29	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3540-3549.	3.3	33
30	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	0.6	30
31	[ $^{18}$ F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 953-962.	3.3	27
32	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	0.6	25
33	Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. <i>Bone Marrow Transplantation</i> , 2021, 56, 1031-1037.	1.3	25
34	Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients—a matched control multicenter cohort study. <i>Haematologica</i> , 2022, 107, 1111-1118.	1.7	25
35	Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2018, 59, 610-616.	0.6	24
36	Hematogenous extramedullary relapse in multiple myeloma—a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24

#	ARTICLE	IF	CITATIONS
37	Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. <i>Human Gene Therapy</i> , 2021, 32, 1224-1241.	1.4	24
38	Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1001-1009.	1.3	23
39	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
40	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 118-124.	0.6	23
41	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2014, 124, 78-78.	0.6	23
42	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
43	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. <i>Molecular Cancer Research</i> , 2019, 17, 2331-2340.	1.5	21
44	Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. <i>Clinical Cancer Research</i> , 2015, 21, 3853-3861.	3.2	20
45	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	0.6	20
46	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
47	Depletion of B cells rejuvenates the peripheral B cell compartment but is insufficient to restore immune competence in aging. <i>Aging Cell</i> , 2019, 18, e12959.	3.0	19
48	Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. <i>Cancer Immunology Research</i> , 2020, 8, 1485-1495.	1.6	19
49	Evaluation of Scpio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1408-1416.	0.7	19
50	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , 2014, 124, 4471-4471.	0.6	19
51	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. <i>Journal of Clinical Oncology</i> , 2018, 36, 8021-8021.	0.8	19
52	Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries. <i>Blood Reviews</i> , 2014, 28, 213-220.	2.8	18
53	The management of hodgkin lymphomas in pregnancies. <i>European Journal of Haematology</i> , 2017, 99, 385-391.	1.1	18
54	Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 -EMERGE Study. <i>Blood</i> , 2012, 120, 905-905.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Romidepsin treatment for relapsed or refractory peripheral and cutaneous Tâ€cell lymphoma: Realâ€life data from a national multicenter observational study. <i>Hematological Oncology</i> , 2019, 37, 569-577.	0.8	17
56	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	0.8	17
57	Peripheral B cells repress B-cell regeneration in aging through a TNF-Î±/IGFBP-1/IGF-1 immune-endocrine axis. <i>Blood</i> , 2021, 138, 1817-1829.	0.6	17
58	Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. <i>Annals of Hematology</i> , 2020, 99, 1273-1281.	0.8	16
59	Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. <i>Annals of Hematology</i> , 2012, 91, 215-221.	0.8	15
60	Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 148-151.	2.5	15
61	Primary plasma cell leukemia in the era of novel agents for myeloma â€“ a multicenter retrospective analysis of outcome. <i>Leukemia Research</i> , 2018, 68, 9-14.	0.4	14
62	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018, 71, 1-5.	0.4	14
63	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2019, 94, 992-1001.	2.0	14
64	Daratumumab for relapsed AL amyloidosisâ€”When cumulative realâ€world data precedes clinical trials: A multisite study and systematic literature review. <i>European Journal of Haematology</i> , 2021, 106, 184-195.	1.1	14
65	Maternal and neonatal outcomes in 80 patients diagnosed with nonâ€Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021, 193, 52-62.	1.2	14
66	Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantationâ€”can preemptive detection of John Cunningham virus be useful?. <i>International Journal of Infectious Diseases</i> , 2014, 26, 107-109.	1.5	13
67	Characteristics and outcomes of young adults with Philadelphiaâ€negative myeloproliferative neoplasms. <i>European Journal of Haematology</i> , 2019, 102, 504-508.	1.1	13
68	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	1.7	13
69	BNT162b2 mRNA COVIDâ€19 vaccine booster induces seroconversion in patients with Bâ€cell nonâ€Hodgkin lymphoma who failed to respond to two prior vaccine doses. <i>British Journal of Haematology</i> , 2022, 196, 1329-1333.	1.2	13
70	Does molecular analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of respiratory infections in hemato-oncological patients?. <i>International Journal of Infectious Diseases</i> , 2016, 50, 48-53.	1.5	12
71	Reduced-dose ICE chemotherapyâ€%Â±â€%rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1633-1639.	0.6	12
72	Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. <i>Blood</i> , 2017, 130, 833-833.	0.6	12

#	ARTICLE	IF	CITATIONS
73	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 735.e5-735.e8.	2.8	12
74	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
75	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. <i>Cancer Cell</i> , 2022, 40, 578-580.	7.7	12
76	A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management. <i>Transplant Immunology</i> , 2013, 28, 57-61.	0.6	11
77	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	0.4	11
78	Impaired migration capacity in monocytes derived from patients with Gaucher disease. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 180-186.	0.6	11
79	Current treatment of lymphoma in pregnancy. <i>Expert Review of Hematology</i> , 2019, 12, 449-459.	1.0	11
80	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
81	Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110352.	1.1	11
82	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014, 124, 950-950.	0.6	11
83	Management of acute myeloid leukemia during pregnancy. <i>Future Oncology</i> , 2014, 10, 1407-1415.	1.1	10
84	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	0.6	10
85	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. <i>Haematologica</i> , 2019, 104, 1798-1803.	1.7	10
86	Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. <i>British Journal of Haematology</i> , 2020, 191, 863-867.	1.2	10
87	Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. <i>European Journal of Haematology</i> , 2022, 108, 52-60.	1.1	10
88	Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8012-8012.	0.8	10
89	Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study. <i>Annals of Hematology</i> , 2017, 96, 271-278.	0.8	9
90	Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 739-748.	2.0	9

#	ARTICLE	IF	CITATIONS
91	The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. <i>British Journal of Haematology</i> , 2020, 189, e31-e33.	1.2	9
92	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	2.0	9
93	Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 1641-1641.	0.6	9
94	Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. <i>Acta Haematologica</i> , 2020, 143, 266-271.	0.7	8
95	Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. <i>Thrombosis Journal</i> , 2021, 19, 79.	0.9	8
96	Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. <i>Annals of Hematology</i> , 2017, 96, 461-467.	0.8	7
97	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. <i>Frontiers in Oncology</i> , 2021, 11, 646971.	1.3	7
98	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.	0.8	6
99	Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. <i>Supportive Care in Cancer</i> , 2018, 26, 2425-2431.	1.0	6
100	Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy – a case series and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 11-17.	1.4	6
101	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	1.1	6
102	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	2.0	6
103	Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation – a retrospective national multicenter study. <i>Annals of Hematology</i> , 2017, 96, 575-579.	0.8	5
104	Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. <i>Journal of Neuro-Oncology</i> , 2021, 151, 211-220.	1.4	5
105	Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?. <i>Cancers</i> , 2022, 14, 750.	1.7	5
106	Hematological malignancies during pregnancy (Review). <i>Molecular and Clinical Oncology</i> , 2019, 10, 3-9.	0.4	4
107	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. <i>Acta Haematologica</i> , 2018, 140, 194-202.	0.7	4
108	Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021, 192, e1-e4.	1.2	4

#	ARTICLE	IF	CITATIONS
109	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 724.	1.1	4
110	REGENâ€COV antibody combination in patients with lymphoproliferative malignancies and SARSâ€CoVâ€2 infection. <i>EJHaem</i> , 2022, 3, 471-474.	0.4	4
111	Conventional allograft and autograft in low grade lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 113-128.	0.7	3
112	Treatment and prognosis of stage I follicular lymphoma in the modern era â€“ does PET matter?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1163-1171.	0.6	3
113	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 489.	1.1	3
114	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
115	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
116	Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience. <i>Blood</i> , 2018, 132, 3259-3259.	0.6	3
117	Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data. <i>Blood</i> , 2019, 134, 5321-5321.	0.6	3
118	Acute Myeloid Leukemia Diagnosed During Pregnancy: Facing Challenges. Systematic Review and Analysis Of 174 Reported Cases. <i>Blood</i> , 2013, 122, 1421-1421.	0.6	3
119	Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 2606-2606.	0.6	3
120	The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data. <i>Leukemia Research</i> , 2020, 97, 106429.	0.4	2
121	Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. <i>European Journal of Haematology</i> , 2020, 105, 30-34.	1.1	2
122	Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 2638-2644.	0.6	2
123	Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 945-952.	0.8	2
124	Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2785-2792.	0.6	2
125	Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party. <i>Blood</i> , 2014, 124, 1195-1195.	0.6	2
126	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	0.6	2



#	ARTICLE	IF	CITATIONS
127	Busulfan Fludarabine Vs. Busulfan Cyclophosphamide As a Preparative Regimen Prior to Allogeneic Hematopoietic Cell Transplantation – Systematic Review and Meta-analysis. <i>Blood</i> , 2014, 124, 3872-3872.	0.6	2
128	Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma. <i>Israel Medical Association Journal</i> , 2016, 18, 411-417.	0.1	2
129	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study. <i>Annals of Hematology</i> , 2018, 97, 459-466.	0.8	1
130	CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines. <i>Leukemia and Lymphoma</i> , 2018, 59, 1878-1883.	0.6	1
131	Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e850-e857.	0.2	1
132	Kinetics of premyelodysplastic syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	0.8	1
133	Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution. <i>Communications Biology</i> , 2020, 3, 29.	2.0	1
134	Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study. <i>Leukemia Research</i> , 2021, 101, 106498.	0.4	1
135	Predictors of Early and Late Mortality for Patients with Hematologic Malignancy and Invasive Mold Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 697.	1.5	1
136	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018, 132, 3295-3295.	0.6	1
137	Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study. <i>Blood</i> , 2018, 132, 1972-1972.	0.6	1
138	Allogeneic Stem Cell Transplantation (ASCT) in CML with Partial T-Cell Depletion, No Prophylaxis for Graft-Versus-Host Disease (GvHD) and Preemptive DLI for Patients with Post-Transplant Minimal Residual Disease (MRD): An Alternative Approach in CML Transplantation with Low Morbidity and Long Term Disease Free Survival.. <i>Blood</i> , 2006, 108, 318-318.	0.6	1
139	Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.. <i>Blood</i> , 2008, 112, 1452-1452.	0.6	1
140	Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 826-826.	0.6	1
141	TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2016, 128, 4377-4377.	0.6	1
142	Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series. <i>Blood</i> , 2016, 128, 5699-5699.	0.6	1
143	Single cell analysis of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8026-8026.	0.8	1
144	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center. <i>Blood</i> , 2021, 138, 3772-3772.	0.6	1
146	Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates. <i>Blood</i> , 2021, 138, 4000-4000.	0.6	1
147	Using Machine Learning Methods to Explore the Role of Non-Coding RNAs in DLBCL. <i>Blood</i> , 2021, 138, 4324-4324.	0.6	1
148	Polatumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	0.8	1
149	Host Factors Affect the Clinical Presentation and Biomarker Sensitivity in Patients with Invasive Pulmonary Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
150	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <i>European Journal of Haematology</i> , 2017, 99, 51-55.	1.1	0
151	Ten Things to Know About Primary Mediastinal B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1959-1960.	2.0	0
152	CA-125 as a Marker for the Early Diagnosis of Hepatic Veno-Occlusive Disease Following Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1138-1138.	0.6	0
153	Use of Dendritic Cells Versus Peripheral Blood Lymphocytes To Segregate Alloreactive and Regulatory T Cells during Allogeneic Transplantation.. <i>Blood</i> , 2005, 106, 5244-5244.	0.6	0
154	Induced CD4+CD25+ FOXP-3+ and CD8+CD25+ FOXP-3+t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities. <i>Blood</i> , 2008, 112, 3501-3501.	0.6	0
155	Absolute Monocyte Count At Diagnosis Is a Poor Prognostic Factor and Impacts Survival in Diffuse Large B-Cell Lymphoma: A Collaborative Multi-Center Study Involving 1026 Patients.. <i>Blood</i> , 2012, 120, 2651-2651.	0.6	0
156	Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2013, 122, 4296-4296.	0.6	0
157	High-Dose Cyclophosphamide In Combination With G-CSF Versus G-CSF Alone For Mobilization Of Hematopoietic Stem Cells After Induction Therapy Including Velcade, Cyclophosphamide and Dexacort. <i>Blood</i> , 2013, 122, 5369-5369.	0.6	0
158	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. <i>Blood</i> , 2014, 124, 3488-3488.	0.6	0
159	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. <i>Blood</i> , 2014, 124, 2132-2132.	0.6	0
160	Efficacy and Safety of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study. <i>Blood</i> , 2014, 124, 3989-3989.	0.6	0
161	Respiratory Infections and Activity of Anti-Flu Vaccine in Patients with Lymphoma and Multiple Myeloma. <i>Blood</i> , 2015, 126, 4617-4617.	0.6	0
162	Different Sources of Stromal Cells Diversely Affect Survival and Trafficking of Mantle Cell Lymphoma Cells. <i>Blood</i> , 2015, 126, 2670-2670.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Prothrombin Complex Concentrate Is Safe and Effective for Achieving Hemostasis in the Setting of Urgent Surgery for Patients Treated with Direct Xa Inhibitors. <i>Blood</i> , 2018, 132, 2541-2541.	0.6	0
164	Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019, 134, 3180-3180.	0.6	0
165	Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study. <i>Blood</i> , 2019, 134, 5654-5654.	0.6	0
166	Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study. <i>Blood</i> , 2019, 134, 5703-5703.	0.6	0
167	Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients. <i>Blood</i> , 2019, 134, 3371-3371.	0.6	0
168	Automated Digital Morphometry of Peripheral Blood Smears Detects Both Infrequent Events and Cellular Population Patterns in Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3999-3999.	0.6	0
169	Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis. <i>Blood</i> , 2021, 138, 2860-2860.	0.6	0
170	A Novel Approach to Blood Smear Analysis Based on Specimen Topology: Implications for Human and Artificial Intelligence Decision Making. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
171	A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
172	Lymphoproliferative disease detected by breast cancer screening. <i>Journal of Medical Screening</i> , 0, , 096914132211099.	1.1	0